Our Team

Soricimed’s experienced team is committed to the development of targeted therapies for solid tumor cancers.

Board of Directors

Vaughn Embro-Pantalony

Chairman

  • Current Board Member and Former CEO of Microbix Biosystems Inc. (TSX:MBX)
  • Former V. P. Finance and Chief Financial Officer of Novopharm Limited; V.P. Information Technology & Chief Information Officer of Bayer Inc.

Thomas Reeves

Director

  • Current President & CEO of Interface Biologics
  • Former President & COO of Occulogix, Inc. (NASDAQ:RHEO)

Marc Rubin

Director

  • Currently Executive Chairman of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
  • Chairman of Galectin Therapeutics (NASDAQ:GALT)
  • Board Member of Curis Inc. (NASDAQ:CRIS)
  • Former Head of Global Research and Development for Bayer Schering Pharma
  • Previous executive roles with Schering AG and GlaxoSmithKline

Susan Hicks

Director

  • President and CEO of Technology Venture Corporation (TVC)

Camille Belliveau

Director

  • Former public accountant and Executive Director of EPR Canada Group

Jack Stewart

Chief Scientific Officer & Director

Paul Gunn

President

Interested in our work?

Join the team

Get in Touch

Management Team

Robert Bruce

Chief Executive Officer

Jack Stewart

Chief Scientific Officer & Director

Paul Gunn

President

Frank Michalargias

Chief Financial Officer

Bob Cory

Vice President, Business Development

Dominique Dugourd

Vice President Research & Development

Tyler Lutes

Senior Scientist

Sam Magee

Financial Analyst

Interested in our work?

Join the team

Get in Touch

Sign up to receive updates from Soricimed

Powered by Innovasium